Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Executive Summary
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.
You may also be interested in...
Biogen Reassessing Gene Therapy From Nightstar Deal After Phase II/III Miss
BIIB112, the gene therapy candidate Biogen picked up in $877m acquisition of Nightstar, missed its primary endpoint in X-linked retinitis pigmentosa. Phase III data for BIIB111, also from Nightstar, are expected soon.
Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies
Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.